UNH vs CVS vs ELV vs CI vs HUM

For growth investors, Elevance Health Inc.

(ELV) is the stronger pick with 12. 6% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Cigna Corporation (CI) offers the better valuation at 12. 4x trailing P/E (9. 1x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.

4x versus CVS Health Corporation at 58. 1x. On forward P/E, Cigna Corporation is actually cheaper at 9. 1x.

Over the past 5 years, Cigna Corporation (CI) delivered a total return of +16.

6%, compared to -44. 3% for Humana Inc. (HUM). Over 10 years, the gap is even starker: UNH returned +217. 0% versus CVS's -2. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus UnitedHealth Group Incorporated's 0. 59β — meaning UNH is approximately 1059% more volatile than CVS relative to the S&P 500. On balance sheet safety, Humana Inc. (HUM) carries a lower debt/equity ratio of 73% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Elevance Health Inc.

(ELV) is pulling ahead at 12. 6% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elevance Health Inc.

(ELV) is the more profitable company, earning 2. 8% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 2. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus 1. 1% for HUM. At the gross margin level — before operating expenses — ELV leads at 25. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Cigna Corporation (CI) trades at 9.

1x forward P/E versus 26. 8x for Humana Inc. — 17. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CI: 19. 0% to $328. 00.

All stocks in this comparison pay dividends.

CVS Health Corporation (CVS) offers the highest yield at 3. 3%, versus 1. 5% for Humana Inc. (HUM).

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 3% yield). Both have compounded well over 10 years (CVS: -2. 2%, HUM: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; ELV is a mid-cap deep-value stock; CI is a mid-cap deep-value stock; HUM is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.